Monoclonal Antibody Therapy Market Size & Trends:
The Monoclonal Antibody Therapy Market size was valued at USD 259.36 billion in 2024 and is expected to reach USD 791.83 billion by 2032, growing at a CAGR of 15.02% over the forecast period of 2025-2032.
To Get more information on Monoclonal Antibody Therapy Market- Request Free Sample Report
The global monoclonal antibody therapy market is witnessing strong growth due to the increasing incidence of cancer, autoimmune disease, and infectious diseases. Progress in antibody engineering, growing approval of target biologics, and extended application in chronic and rare diseases drive the demand. Moreover, increasing R&D spending, favorable reimbursement scenario, and biosimilars penetration are increasing the market penetration.
The U.S. monoclonal antibody therapy market size was valued at USD 75.61 billion in 2024 and is expected to reach USD 223.37 billion by 2032, growing at a CAGR of 14.54% over the forecast period of 2025-2032.
The monoclonal antibody therapy market in North America is dominated by the U.S. owing to the strong biotechnology industry, developed healthcare infrastructure, and large investments in R&D. The market has benefited from the early introduction of new biologics, a relatively fast and efficient regulatory approval process, and the presence of large pharmaceutical companies such as Amgen, AbbVie, and Pfizer. Wide access to treatment and accommodating reimbursement policies further secure the U.S.’s position as a leader in the region.
In May 2025, telisotuzumab vedotin (Emrelis by AbbVie), an antibody-drug conjugate (ADC) that targets c-Met for NSCLC, was granted FDA accelerated approval, highlighting the rise of novel antibody-drug therapies.
Monoclonal Antibody Therapy Market Dynamics:
Drivers
-
Support from Advances in Biotechnological Research and mAb Engineering is a Key factor for the Growth of the Market
Recent advances in biotechnology have revolutionized the mAb development. Recent advances in recombinant DNA technology, phage display, and transgenic mouse models have facilitated the development of humanized and human antibodies that minimize immunogenicity and patient irritation. These truncated antibodies provide improved specificity for their antigens, and also reduce any associated side effects that occur due to binding to non-antibody molecules that may be present. Furthermore, optimized expression systems and bioproduction processes have made the production of mAbs on an industrial scale increasingly efficient and economically viable.
As per ScienceDirect, artificial intelligence and machine learning platforms are now drastically speeding up therapeutic antibody discovery, with in silico screening, optimized binding affinity, and a slash in expensive lab tests.
Novel generative AI technologies are applied to humanizing antibodies, resulting in diverse candidates with lower immunogenicity and maintained therapeutic binding, increasing the safety and efficacy in next-gen monoclonal antibodies.
-
The Rising Prevalence of Oncology Therapeutics is Driving the Market Growth
Oncology is the largest application area for monoclonal antibodies, which selectively bind to antigens on the surface of cancer cells or stimulate an immune response to tumor cells. Checkpoint inhibitors, such as nivolumab and pembrolizumab, and antibody-drug conjugates, like trastuzumab emtansine, have introduced new paradigms of care in cancer treatment. Given the solid clinical pipeline and trials that continue to evaluate mAbs for a range of cancers, including breast, lung, colorectal, and hematological cancers, their use will continue to increase. Moreover, combination therapies with mAbs with chemotherapy or other immunotherapies have demonstrated increased effectiveness, driving the monoclonal antibody therapy market growth.
In a Frontiers in Immunology review, it is noted that in the recent three years, 18 FDA and EMA approvals of monoclonal antibodies have occurred in the field of oncology, predominantly as bispecific antibodies (BsAb) or antibody‑drug conjugates (ADC), thus illustrating the pace of progress and regulatory momentum.
It also consented to AstraZeneca’s human monoclonal antibody Imfinzi (durvalumab) for limited-stage small cell lung cancer development in late 2024, indicating increased indications and access in the cancer immunotherapy space.
Restraint
-
The High Cost of Monoclonal Antibody Therapy is Restraining the Market from Growing
Monoclonal antibodies are one of the most expensive types of drugs in modern medicine, since it is extremely complicated and expensive to develop and produce them. To make these mAbs, sophisticated biotechnology methods are employed, which use living cells, bioreactors, and very strict environments. Furthermore, maintaining the activity, effectiveness, and safety of such biologics results in significant regulatory and quality control costs. Apart from production, there are storage (cold chain logistics), clinical trials, and post-marketing surveillance costs as well, that add to the total cost of treatment.
Therapies such as these cost from thousands to tens of thousands of dollars per course of treatment, prices that make them out of reach for many patients, particularly in countries where healthcare coverage possibilities are rather restricted. Even in rich markets, the costs can place a strain on health care budgets and restrict the provision of insurance coverage and the availability of patient access. Therefore, in spite of their favorable therapeutic efficacy, the prohibitive cost represents a major challenge to expanded use of monoclonal antibody–based therapies globally.
Monoclonal Antibody Therapy Market Segmentation Analysis:
By Type
Human mAb segment dominated the monoclonal antibody therapy market share in 2024, with a 42.15% growth of this segment can primarily be attributed to the availability of a superior therapeutic profile, less immunogenicity, and well-established clinical reorganization. Human monoclonal antibodies are designed to mimic natural antibodies in the human system and thereby significantly reduce the possibility of an adverse immune reaction when compared to that of either a chimeric or murine antibody. Their widespread application in the treatment of chronic diseases such as cancer, autoimmunity, and infectious diseases has established their domination, as has the approval of blockbuster drugs such as adalimumab and pembrolizumab.
Humanized mAbs segment is anticipated to exhibit the fastest CAGR during the forecast period, primarily due to the development of new antibody engineering technologies and a robust pipeline of next-generation therapeutics. Humanized monoclonal antibodies provide a strategic means of balancing efficacy with manufacturability, allowing for targeting of a wide range of disease pathways without the side effects seen in earlier classes of antibodies. Growing investment in research, expanded usage for a range of therapeutic areas, and strong regulatory backing for biosimilars are key factors propelling their swift uptake.
By Application
The cancer segment accounted for the largest share in the monoclonal antibody therapy market with 39.5% in 2024 due to the high prevalence of various types of cancer globally and an increase in demand for targeted therapies. Monoclonal antibodies have revolutionized cancer therapy with the precision targeting of tumor antigens, sparing of normal tissue, and improved patient outcomes. Agents including rituximab, trastuzumab, and nivolumab have redefined the landscape of cancer care. Strong investment in cancer R&D, ongoing clinical trials, and supportive regulatory approvals were also key in establishing this segment’s dominance.
The autoimmune diseases segment is expected to expand at the highest CAGR over the forecast period as the prevalence rate of diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease continues to surge. Witnessing greater awareness, a broadening of treatment use, a more optimistic outlook, and the introduction of biologics such as adalimumab and ustekinumab. Furthermore, compared with conventional immunosuppressants, monoclonal antibodies present advantages of specificity and efficiency, which are more favored by physicians and patients.
By Distribution Channel
The Hospital pharmacy segment leads the monoclonal antibody therapy market share in 2024 with 45.5%. As monoclonal antibody therapy is complex to administer, it demands clinical monitoring and aseptic conditions during infusion/injection. Hospitals are the sites where a majority of the cases of MAb treatments are present for cancer, autoimmune diseases, and infectious diseases. Additionally, the reimbursement system, high-cost biologics available on the market, and the centralized drug purchasing model in the hospital enhanced the dominance.
The retail pharmacy segment is expected to grow at the fastest CAGR throughout the forecast period, attributed to the growing access to subcutaneous and self-administered monoclonal antibody formulations. Security of RA biologics has become a critical issue, with healthcare being increasingly patient-centric and biologics being more convenient to handle out of the hospital; new pathways for access through retail pharmacies are being developed. Increasing use of outpatient treatments, patients seeking homecare options, and extension of specialty pharmacies also help to drive this channel.
By End User
The hospitals segment led the monoclonal antibody therapy market in 2024, due to their extensive infrastructural facilities coupled with the advanced infusion centers for treating complicated cases requiring specialist care. Hospitals are the first point of care for serious conditions such as cancer, autoimmune diseases, and infectious diseases, frequent indications for monoclonal antibody treatments. In the hospital, patients are well supervised for possible adverse reactions, particularly regarding initial dosing, which is so important for biologics with high immunogenicity.
The specialty clinics segment is expected to witness significant growth over the forecast years as a result of growing inclination towards decentralized healthcare, along with a surge in demand for outpatient treatment facilities. Specialty clinics, focusing on areas such as oncology, immunology, or dermatology, provide targeted, personalized care and quicker access to biologic treatments. The convenience of encounter, ease of access, comparatively lesser waiting times in OPD, and convenience in the management of a chronic disease are some of the reasons responsible for the preference of CPHC over hospitals for outpatient consultation, especially in urban/semi-urban areas.
Monoclonal Antibody Therapy Market Regional Insights:
North America leads the global monoclonal antibody therapy market analysis with around 38.3% market share in 2024 on account of robust pharmaceutical & biotechnology infrastructure in the region, stringent regulations, and high healthcare spending. Home to big names such as Amgen, Johnson & Johnson, Pfizer, and AbbVie, a thriving biotech industry drives new product development. Also, favorable compensation and high penetration of advanced therapies, combined with easy availability of healthcare services, play an important role in propelling the region to its dominant position.
The Asia Pacific region is developing as the fastest-growing market in the monoclonal antibody therapy market due to the growing healthcare sector, growing awareness about biologics, and large investments made by pharmaceutical companies for R&D activities. China, India, Japan, and South Korea, among others, are witnessing an increased burden of chronic diseases, and this is propelling the demand for focused treatments such as monoclonal antibodies. The prospect of higher government efforts to facilitate biologics access and the rising hub of local biosimilar producers and clinical trials are crucial factors for regional market expansion.
High healthcare standards, a well-established biopharmaceutical industry, and a favorable regulatory scenario are responsible for the vigorous growth in the European monoclonal antibody therapy market. Leaders in countries such as Germany, the UK, France, and Switzerland are driving this trend, supported by government-backed R&D programmes and rising numbers of Big Pharma investments. Europe’s EMA also has efficient approval pathways, which allow for faster access to new therapies. Furthermore, the existence of key biopharma companies and growing biosimilar uptake are also likely to drive the market in the region.
MEA and Latin America are also showing moderate development in the monoclonal antibody therapy market due to favourable healthcare infrastructure and rising usage of the advanced treatment options. In Latin America, Brazil, Mexico, and Argentina are increasing their offerings in biologic therapy, but it has not spread due to cost limitations, immature insurance systems, and lower per capita spending on healthcare.
Government-supported healthcare modernization efforts, public-private partnerships, and the increasing burden of chronic diseases are driving the growth in the MEA. Major urban centres of the Gulf and South Africa present potential for biologics uptake, though overall market penetration is constrained by complex regulations, supply constraints, and affordability concerns, which translate to a steady but not explosive growth perspective for the region.
Get Customized Report as per Your Business Requirement - Enquiry Now
Monoclonal Antibody Therapy Market Key Players:
The monoclonal antibody therapy market companies are Roche Holding AG, AbbVie Inc., Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., AstraZeneca PLC, GlaxoSmithKline plc (GSK), Sanofi S.A., Eli Lilly and Company, Biogen Inc., Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Genmab A/S, UCB S.A., Seagen Inc., Bayer AG, BeiGene Ltd., and other players.
Recent Developments in the Monoclonal Antibody Therapy Market:
-
June 2025 – Roche decided to push prasinezumab, a research anti-alpha-synuclein monoclonal antibody, into Phase III clinical development to treat early-stage Parkinson's disease. The choice stems from promising data from the Phase IIb PADOVA study and observations from the ongoing open-label extension (OLE) studies of the PADOVA and Phase II PASADENA trials.
-
February 2024 – AbbVie Inc. and OSE Immunotherapeutics SA have entered a strategic collaboration to co-develop OSE-230, a monoclonal antibody in pre-clinical stages of development. The drug is intended to reverse chronic and severe inflammation, marking a new therapy strategy in immunotherapy.
Report Attributes Details Market Size in 2024 USD 259.36 Billion Market Size by 2032 USD 791.83 Billion CAGR CAGR of 15.02% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Report Scope & Coverage Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook Key Segments • By Type (Human mAb, Humanized mAb, Chimeric mAb, Murine mAb)
• By Application (Cancer, Autoimmune Diseases, Infectious Diseases, Hematological Disorders, Ophthalmological Conditions, Others [e.g., Cardiovascular, Respiratory])
• By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
• By End User (Hospitals, Specialty Clinics, Research Institutes, Homecare Settings)Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Company Profiles The monoclonal antibody therapy market companies are Roche Holding AG, AbbVie Inc., Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., AstraZeneca PLC, GlaxoSmithKline plc (GSK), Sanofi S.A., Eli Lilly and Company, Biogen Inc., Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Genmab A/S, UCB S.A., Seagen Inc., Bayer AG, BeiGene Ltd., and other players.
Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Type
2.3.2 Market Size By Application
2.3.2 Market Size By Distribution Channel
2.3.2 Market Size By End User
2.4 Market Share & Bps Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Incidence and Prevalence Trends (2024)
4.1.1 Global prevalence of cancer, autoimmune, and infectious diseases
4.1.2 Incidence trends of HER2+ breast cancer, RA, MS, and COVID-19
4.1.3 Regional burden of chronic diseases driving mAb demand
4.2 Treatment Uptake & Prescription Trends (2024), by Region
4.2.1 Prescription rate of mAbs across key regions (North America, Europe, Asia Pacific)
4.2.2 Trends in biosimilar mAb adoption in price-sensitive markets
4.2.3 Expansion of first-line use of mAbs in oncology and immunology
4.3 mAb Therapy Production & Supply Volume, by Region (2020–2032)
4.3.1 Regional manufacturing capacities and annual production volumes
4.3.2 CDMO outsourcing trends for monoclonal antibody production
4.3.3 Investments in upstream/downstream bioprocessing and bioreactors
4.4 Healthcare Spending on mAb Therapy, by Region (2024)
4.4.1 Government healthcare expenditure on biologics
4.4.2 Commercial insurance and private sector share
4.4.3 Regional out-of-pocket spending on mAb therapies
4.4.4 Public reimbursement schemes and national funding programs
4.5 R&D Investment & Pipeline Dynamics (2024)
4.5.1 Total R&D expenditure on monoclonal antibody therapy development
4.5.2 Growth in pipeline assets: INDs and Phase I–III trials
4.5.3 Strategic alliances and licensing agreements in the mAb segment
5. Monoclonal Antibody Therapy Market Segmental Analysis & Forecast, By Type, 2021 – 2032, Value (USD Billion)
5.1 Introduction
5.2 Human mAb
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.3 Humanized mAb
5.3.1 Key Trends
5.3.2 Market Size & Forecast, 2021 – 2032
5.4 Chimeric mAb
5.4.1 Key Trends
5.4.2 Market Size & Forecast, 2021 – 2032
5.5 Murine mAb
5.5.1 Key Trends
5.5.2 Market Size & Forecast, 2021 – 2032
6. Monoclonal Antibody Therapy Market Segmental Analysis & Forecast, By Application, 2021 – 2032, Value (USD Billion)
6.1 Introduction
6.2 Cancer
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Autoimmune Diseases
6.3.1 Key Trends
6.3.2 Market Size & Forecast, 2021 – 2032
6.4 Infectious Diseases
6.4.1 Key Trends
6.4.2 Market Size & Forecast, 2021 – 2032
6.5 Hematological Disorders
6.5.1 Key Trends
6.5.2 Market Size & Forecast, 2021 – 2032
6.6 Ophthalmological Conditions
6.6.1 Key Trends
6.6.2 Market Size & Forecast, 2021 – 2032
6.7 Others
6.7.1 Key Trends
6.7.2 Market Size & Forecast, 2021 – 2032
7. Monoclonal Antibody Therapy Market Segmental Analysis & Forecast, By Distribution Channel, 2021 – 2032, Value (USD Billion)
7.1 Introduction
7.2 Hospital Pharmacy
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 Retail Pharmacy
7.3.1 Key Trends
7.3.2 Market Size & Forecast, 2021 – 2032
7.4 Online Pharmacy
7.4.1 Key Trends
7.4.2 Market Size & Forecast, 2021 – 2032
8. Monoclonal Antibody Therapy Market Segmental Analysis & Forecast, By Vertical, 2021 – 2032, Value (USD Billion)
8.1 Introduction
8.2 Hospitals
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2021 – 2032
8.3 Specialty Clinics
8.3.1 Key Trends
8.3.2 Market Size & Forecast, 2021 – 2032
8.4 Research Institutes
8.4.1 Key Trends
8.4.2 Market Size & Forecast, 2021 – 2032
8.5 Homecare Settings
8.5.1 Key Trends
8.5.2 Market Size & Forecast, 2021 – 2032
9. Monoclonal Antibody Therapy Market Segmental Analysis & Forecast By Region, 2021 – 2025, Value (USD Billion)
9.1 Introduction
9.2 North America
9.2.1 Key Trends
9.2.2 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.2.3 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.2.4 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.2.5 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.2.6 Monoclonal Antibody Therapy Market Size & Forecast, By Country, 2021 – 2032
9.2.6.1 USA
9.2.6.1.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.2.6.1.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.2.6.1.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.2.6.1.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.2.6.2 Canada
9.2.6.2.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.2.6.2.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.2.6.2.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.2.6.2.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.3 Europe
9.3.1 Key Trends
9.3.2 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.3.3 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.3.4 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.5 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.3.6 Monoclonal Antibody Therapy Market Size & Forecast, By Country, 2021 – 2032
9.3.6.1 Germany
9.3.6.1.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.3.6.1.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.3.6.1.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6.1.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.3.6.2 UK
9.3.6.2.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.3.6.2.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.3.6.2.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6.2.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.3.6.3 France
9.3.6.3.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.3.6.3.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.3.6.3.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6.3.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.3.6.4 Italy
9.3.6.4.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.3.6.4.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.3.6.4.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6.4.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.3.6.5 Spain
9.3.6.5.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.3.6.5.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.3.6.5.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6.5.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.3.6.6 Russia
9.3.6.6.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.3.6.6.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.3.6.6.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6.6.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.3.6.7 Poland
9.3.6.7.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.3.6.7.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.3.6.7.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6.7.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.3.6.8 Rest of Europe
9.3.6.8.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.3.6.8.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.3.6.8.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.3.6.8.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.4 Asia-Pacific
9.4.1 Key Trends
9.4.2 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.4.3 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.4.4 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4.5 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.4.6 Monoclonal Antibody Therapy Market Size & Forecast, By Country, 2021 – 2032
9.4.6.1 China
9.4.6.1.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.4.6.1.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.4.6.1.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4.6.1.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.4.6.2 India
9.4.6.2.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.4.6.2.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.4.6.2.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4.6.2.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.4.6.3 Japan
9.4.6.3.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.4.6.3.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.4.6.3.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4.6.3.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.4.6.4 South Korea
9.4.6.4.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.4.6.4.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.4.6.4.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4.6.4.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.4.6.5 Australia
9.4.6.5.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.4.6.5.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.4.6.5.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4.6.5.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.4.6.6 ASEAN Countries
9.4.6.6.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.4.6.6.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.4.6.6.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4.6.6.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.4.6.7 Rest of Asia-Pacific
9.4.6.7.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.4.6.7.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.4.6.7.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.4.6.7.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.5 Latin America
9.5.1 Key Trends
9.5.2 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.5.3 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.5.4 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.5.5 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.5.6 Monoclonal Antibody Therapy Market Size & Forecast, By Country, 2021 – 2032
9.5.6.1 Brazil
9.5.6.1.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.5.6.1.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.5.6.1.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.5.6.1.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.5.6.2 Argentina
9.5.6.2.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.5.6.2.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.5.6.2.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.5.6.2.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.5.6.3 Mexico
9.5.6.3.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.5.6.3.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.5.6.3.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.5.6.3.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.5.6.4 Colombia
9.5.6.4.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.5.6.4.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.5.6.4.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.5.6.4.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.5.6.5 Rest of Latin America
9.5.6.5.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.5.6.5.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.5.6.5.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.5.6.5.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.6 Middle East & Africa
9.6.1 Key Trends
9.6.2 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.6.3 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.6.4 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.6.5 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.6.6 Monoclonal Antibody Therapy Market Size & Forecast, By Country, 2021 – 2032
9.6.6.1 UAE
9.6.6.1.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.6.6.1.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.6.6.1.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.6.6.1.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.6.6.2 Saudi Arabia
9.6.6.2.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.6.6.2.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.6.6.2.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.6.6.2.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.6.6.3 Qatar
9.6.6.3.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.6.6.3.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.6.6.3.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.6.6.3.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.6.6.4 Egypt
9.6.6.4.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.6.6.4.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.6.6.4.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.6.6.4.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.6.6.5 South Africa
9.6.6.5.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.6.6.5.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.6.6.5.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.6.6.5.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
9.6.6.6 Rest of Middle East & Africa
9.6.6.6.1 Monoclonal Antibody Therapy Market Size & Forecast, By Application, 2021 – 2032
9.6.6.6.2 Monoclonal Antibody Therapy Market Size & Forecast, By Type, 2021 – 2032
9.6.6.6.3 Monoclonal Antibody Therapy Market Size & Forecast, By Distribution Channel, 2021 – 2032
9.6.6.6.4 Monoclonal Antibody Therapy Market Size & Forecast, By End User, 2021 – 2032
10. Competitive Landscape
10.1 Key Players' Positioning
10.2 Competitive Developments
10.2.1 Key Strategies Adopted (%), By Key Players, 2024
10.2.2 Year-Wise Strategies & Development, 2021 – 2025
10.2.3 Number Of Strategies Adopted By Key Players, 2024
10.3 Market Share Analysis, 2024
10.4 Product/Service & Application Benchmarking
10.4.1 Product/Service Specifications & Features By Key Players
10.4.2 Product/Service Heatmap By Key Players
10.4.3 Application Heatmap By Key Players
10.5 Industry Start-Up & Innovation Landscape
10.6 Key Company Profiles
10.6 Key Company Profiles
10.6.1 Roche Holding AG
10.6.1.1 Company Overview & Snapshot
10.6.1.2 Product/Service Portfolio
10.6.1.3 Key Company Financials
10.6.1.4 SWOT Analysis
10.6.2 AbbVie Inc.
10.6.2.1 Company Overview & Snapshot
10.6.2.2 Product/Service Portfolio
10.6.2.3 Key Company Financials
10.6.2.4 SWOT Analysis
10.6.3 Johnson & Johnson
10.6.3.1 Company Overview & Snapshot
10.6.3.2 Product/Service Portfolio
10.6.3.3 Key Company Financials
10.6.3.4 SWOT Analysis
10.6.4 Amgen Inc.
10.6.4.1 Company Overview & Snapshot
10.6.4.2 Product/Service Portfolio
10.6.4.3 Key Company Financials
10.6.4.4 SWOT Analysis
10.6.5 Bristol-Myers Squibb Company
10.6.5.1 Company Overview & Snapshot
10.6.5.2 Product/Service Portfolio
10.6.5.3 Key Company Financials
10.6.5.4 SWOT Analysis
10.6.6 Merck & Co., Inc.
10.6.6.1 Company Overview & Snapshot
10.6.6.2 Product/Service Portfolio
10.6.6.3 Key Company Financials
10.6.6.4 SWOT Analysis
10.6.7 Novartis AG
10.6.7.1 Company Overview & Snapshot
10.6.7.2 Product/Service Portfolio
10.6.7.3 Key Company Financials
10.6.7.4 SWOT Analysis
10.6.8 Pfizer Inc.
10.6.8.1 Company Overview & Snapshot
10.6.8.2 Product/Service Portfolio
10.6.8.3 Key Company Financials
10.6.8.4 SWOT Analysis
10.6.9 AstraZeneca PLC
10.6.9.1 Company Overview & Snapshot
10.6.9.2 Product/Service Portfolio
10.6.9.3 Key Company Financials
10.6.9.4 SWOT Analysis
10.6.10 GlaxoSmithKline plc (GSK)
10.6.10.1 Company Overview & Snapshot
10.6.10.2 Product/Service Portfolio
10.6.10.3 Key Company Financials
10.6.10.4 SWOT Analysis
10.6.11 Sanofi S.A.
10.6.11.1 Company Overview & Snapshot
10.6.11.2 Product/Service Portfolio
10.6.11.3 Key Company Financials
10.6.11.4 SWOT Analysis
10.6.12 Eli Lilly and Company
10.6.12.1 Company Overview & Snapshot
10.6.12.2 Product/Service Portfolio
10.6.12.3 Key Company Financials
10.6.12.4 SWOT Analysis
10.6.13 Biogen Inc.
10.6.13.1 Company Overview & Snapshot
10.6.13.2 Product/Service Portfolio
10.6.13.3 Key Company Financials
10.6.13.4 SWOT Analysis
10.6.14 Regeneron Pharmaceuticals Inc.
10.6.14.1 Company Overview & Snapshot
10.6.14.2 Product/Service Portfolio
10.6.14.3 Key Company Financials
10.6.14.4 SWOT Analysis
10.6.15 Takeda Pharmaceutical Company Limited
10.6.15.1 Company Overview & Snapshot
10.6.15.2 Product/Service Portfolio
10.6.15.3 Key Company Financials
10.6.15.4 SWOT Analysis
10.6.16 Genmab A/S
10.6.16.1 Company Overview & Snapshot
10.6.16.2 Product/Service Portfolio
10.6.16.3 Key Company Financials
10.6.16.4 SWOT Analysis
10.6.17 UCB S.A.
10.6.17.1 Company Overview & Snapshot
10.6.17.2 Product/Service Portfolio
10.6.17.3 Key Company Financials
10.6.17.4 SWOT Analysis
10.6.18 Seagen Inc.
10.6.18.1 Company Overview & Snapshot
10.6.18.2 Product/Service Portfolio
10.6.18.3 Key Company Financials
10.6.18.4 SWOT Analysis
10.6.19 Bayer AG
10.6.19.1 Company Overview & Snapshot
10.6.19.2 Product/Service Portfolio
10.6.19.3 Key Company Financials
10.6.19.4 SWOT Analysis
10.6.20 BeiGene Ltd.
10.6.20.1 Company Overview & Snapshot
10.6.20.2 Product/Service Portfolio
10.6.20.3 Key Company Financials
10.6.20.4 SWOT Analysis
11. Analyst Recommendations
11.1 SNS Insider Opportunity Map
11.2 Industry Low-Hanging Fruit Assessment
11.3 Market Entry & Growth Strategy
11.4 Analyst Viewpoint & Suggestions On Market Growth
12. Assumptions
13. Disclaimer
14. Appendix
14.1 List Of Tables
14.2 List Of Figures
Key Market Segments:
By Type
- Human mAb
- Humanized mAb
- Chimeric mAb
- Murine mAb
By Application
- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Hematological Disorders
- Ophthalmological Conditions
- Others (e.g., Cardiovascular, Respiratory)
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By End User
- Hospitals
- Specialty Clinics
- Research Institutes
- Homecare Settings
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- ASEAN Countries
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- Egypt
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Mexico
- Colombia
- Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
- Detailed Volume Analysis
- Criss-Cross segment analysis (e.g., Product X Application)
- Competitive Product Benchmarking
- Geographic Analysis
- Additional countries in any of the regions
- Customized Data Representation
- Detailed analysis and profiling of additional market players
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
